← Back to Screener
Moleculin Biotech, Inc. (MBRX)
Price$2.56
Favorite Metrics
Price vs S&P 500 (26W)-88.33%
Price vs S&P 500 (4W)7.98%
Market Capitalization$13.66M
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)1.71x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-11.34
Price vs S&P 500 (YTD)-31.03%
EPS (TTM)$-46.92
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-46.92
EPS (Annual)$-158.02
ROI (Annual)-363.99%
Cash / Share (Quarterly)$3.39
ROA (Last FY)-128.58%
EBITD / Share (TTM)$-22.00
ROE (5Y Avg)-130.32%
Cash Flow / Share (Annual)$-176.64
P/B Ratio325.26x
P/B Ratio (Quarterly)324.54x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-6.48x
ROA (TTM)-207.09%
EPS Incl Extra (Annual)$-158.02
Current Ratio (Annual)0.97x
Quick Ratio (Quarterly)1.18x
3-Month Avg Trading Volume0.26M
52-Week Price Return-89.47%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.56
52-Week High$28.61
EPS Excl Extra (Annual)$-158.02
CapEx CAGR (5Y)-24.21%
Tangible BV CAGR (5Y)36.72%
26-Week Price Return-79.58%
Quick Ratio (Annual)0.80x
13-Week Price Return-41.55%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.39x
Enterprise Value$6.958
Book Value / Share Growth (5Y)7.61%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$31.65
3-Month Return Std Dev112.53%
Net Income / Employee (TTM)$-2
ROE (Last FY)-363.99%
Net Interest Coverage (Annual)-10.97x
EPS Basic Excl Extra (Annual)$-158.02
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-46.92
ROI (TTM)-297.76%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$6.70
Price vs S&P 500 (52W)-124.56%
Year-to-Date Return-26.89%
5-Day Price Return-11.03%
EPS Normalized (Annual)$-158.02
ROA (5Y Avg)-67.14%
Month-to-Date Return5.68%
Cash Flow / Share (TTM)$-0.89
EBITD / Share (Annual)$-161.10
ROI (5Y Avg)-130.32%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-46.92
P/TBV (Quarterly)1.22x
P/B Ratio (Annual)0.85x
Book Value / Share (Annual)$44.24
Price vs S&P 500 (13W)-44.41%
Beta1.75x
Revenue / Share (TTM)$0.00
ROE (TTM)-297.76%
52-Week Low$1.79
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.11
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
MBRXMoleculin Biotech, Inc. | — | — | — | — | $2.56 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Moleculin Biotech is a clinical-stage biopharmaceutical company developing a portfolio of drug candidates for resistant cancers and viral infections. The company's lead program, Annamycin, is a next-generation anthracycline designed to overcome multidrug resistance while reducing cardiotoxic side effects.